ClinicalTrials.gg
CompletedNCT00662649Updated Jul 12, 2012Results posted

Long-term Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis

A Phase 3 interventional study of Fingolimod 0.5 mg and Fingolimod 1.25 mg in Multiple Sclerosis, sponsored by Novartis. Completed at 105 sites in 22 countries. Open to participants aged 20 Years to 58 Years. Per ClinicalTrials.gov, last updated 2012-07-12.

Sponsored by Novartis · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
920
Allocation
Randomized
Ages
20 Years to 58 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies testing fingolimod in Multiple Sclerosis — 2 open to participants now, 4 under way, 3 of them phase 3. fingolimod · Multiple Sclerosis.

Enrollment
8th of 34
920 · median 167
Started
2008
with 2 others
Phase 3
12 of 34
1 open now
Registered
6th of 34
by date
Lead sponsor
10 of 34
Novartis

Among the 34 studies testing fingolimod in Multiple Sclerosis, this one is the 8th largest by enrollment, is one of 3 that started in 2008, is one of 12 in phase 3, and was the 6th registered.

Multiple Sclerosis

3,271 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

2 of the 34 studies testing fingolimod in Multiple Sclerosis are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About fingolimod

fingolimod: first FDA approval 2010 (GILENYA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 433 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.

This study: 20 Years to 58 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing fingolimod in Multiple Sclerosis, or all of them as a file.
02

Study summary

This extension study of was designed to evaluate the long-term safety, tolerability, and efficacy of fingolimod (FTY720) in patients with multiple sclerosis. The Extension study was an extension to the 24-month Core study (CFTY720D2301/NCT00289978).

03

Conditions studied

  • Multiple Sclerosis

Browse trials for

Keywords

  • Multiple sclerosis.
  • Relapse-remitting
  • Fingolimod
04

Who can participate

Ages eligible
20 Years to 58 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients should complete the 24 month core study

Exclusion criteria

Exclusion Criteria:

  • Patients with other chronic disease of the immune system, , acute pulmonary disease, cardiac failure, etc.
  • Pregnant or nursing women

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
920 participants (actual)

Study arms

  • Experimental
    Fingolimod 1.25 mg

    Patients continued the same dose to which they had been randomized in the Core study (CFTY720D2301/NCT00289978), fingolimod 1.25 mg/day, in this Extension study.

    Drug: Fingolimod 1.25 mg

  • Experimental
    Fingolimod 0.5 mg

    Patients continued the same dose to which they had been randomized in the Core study, fingolimod 0.5 mg/day, in this Extension study.

    Drug: Fingolimod 0.5 mg

  • Experimental
    Placebo-fingolimod

    Patients randomized to placebo in the Core study were re randomized to fingolimod (either 0.5 or 1.25 mg/day) in this Extension study.

    Drug: Fingolimod 0.5 mg · Drug: Fingolimod 1.25 mg

  • Experimental
    Placebo-fingolimod 1.25 mg

    Patients randomized to placebo in the Core study were re randomized to fingolimod 1.25 mg/day in this Extension study.

    Drug: Fingolimod 1.25 mg

  • Experimental
    Placebo-fingolimod 0.5 mg

    Patients randomized to placebo in the Core study were re randomized to fingolimod 0.5 mg/day in this Extension study.

    Drug: Fingolimod 0.5 mg

Interventions

  • Patients self-administered fingolimod 0.5 mg capsules orally once daily.

    Also known as: FTY720

  • Patients self-administered fingolimod 1.25 mg capsules orally once daily.

    Also known as: FTY720

06

What researchers measure

Primary outcomes

  1. Annualized Aggregate Relapse Rate (ARR) During Months 0 to End of Study(Core [CFTY720D2301/NCT00289978] and Extension Study)

    ARR is defined as the number of confirmed relapses in a year. A relapse is defined as the appearance of a new or worsening of a previously stable or improving pre-existing neurological abnormality, separated by at least 30 days from onset of a preceding relapse. The abnormality must be present for at least 24 hours and occur in the absence of fever or infection. The annualized ARR for each treatment group was the mean of the annualized ARRs for all patients in the group, calculated as the total number of confirmed relapses divided by the total number of days on study multiplied by 365.25.

    Time frame: Months 0 to end of study (maximum up to 60 months)

  2. Time to First Confirmed Relapse up to End of Study: Kaplan-Meier Estimate of Percentage of Patients Relapse-free

    A relapse was confirmed when it was accompanied by an increase of at least half a step (0.5) on the Expanded Disability Status Scale (EDSS) or an increase of 1 point on two different Functional Systems (FS) of the EDSS or 2 points on one of the FS (excluding Bowel/Bladder or Cerebral FS). Kaplan-Meier estimates of the percentage of relapse-free patients at end of study and and 95% confidence intervals (CIs) were presented for the treatment groups.

    Time frame: Core baseline to end of study (maximum up to 60 months)

  3. Annualized Aggregate Relapse Rate (ARR) During Months 0-24 (Core Study) and Months 24-48 (Extension Study)

    ARR is defined as the number of confirmed relapses in a year. A relapse is defined as the appearance of a new or worsening of a previously stable or improving pre-existing neurological abnormality, separated by at least 30 days from onset of a preceding relapse. The abnormality must be present for at least 24 hours and occur in the absence of fever or infection. The annualized ARR for each treatment group was the mean of the annualized ARRs for all patients in the group, calculated as the total number of confirmed relapses divided by the total number of days on study multiplied by 365.25.

    Time frame: Months 0-24 (core study) and Months 24-48 (extension study)

  4. Change (Expressed as Ratio) in the Annualized Aggregate Relapse Rate (ARR) From Months 0-24 (Core Study) to Months 24-48 (Extension Study)

    ARR is defined as the number of confirmed relapses in a year. A relapse is defined as the appearance of a new or worsening of a previously stable or improving pre-existing neurological abnormality, separated by at least 30 days from onset of a preceding relapse. The abnormality must be present for at least 24 hours and occur in the absence of fever or infection. The annualized ARR for each treatment group was the mean of the annualized ARRs for all patients in the group, calculated as the total number of confirmed relapses divided by the total number of days on study multiplied by 365.25.

    Time frame: Months 0-24 (core study) and Months 24-48 (extension study)

Secondary outcomes

  1. Change in Mean Number of New or Newly Enlarged T2 Magnetic Resonance Imaging (MRI) Lesions During Months 0-24 (Core Study) and Months 24-48 (Extension Study)

    The number of new or newly enlarged T2 lesions was assessed with T2-weighted MRI scans. A T2-weighted MRI scan utilizes particular values of the echo time (TE) and the repetition time (TR) parameters of image acquisition. Inflammation and tissue damage are seen as bright areas in T2 images and are often referred to as T2 lesions. T2 weighted MRI scans are a sensitive way to evaluate the brain for demyelinating diseases, such as multiple sclerosis.

    Time frame: Months 0-24 (core study) and Months 24-48 (extension study)

  2. Percentage of Patients Free of New or Newly Enlarged T2 Magnetic Resonance Imaging (MRI) Lesions During Months 0-24 (Core Study) and Months 24-48 (Extension Study)

    The number of new or newly enlarged T2 lesions was assessed with T2-weighted MRI scans. A T2-weighted MRI scan utilizes particular values of the echo time (TE) and the repetition time (TR) parameters of image acquisition. Inflammation and tissue damage are seen as bright areas in T2 images and are often referred to as T2 lesions. T2 weighted MRI scans are a sensitive way to evaluate the brain for demyelinating diseases, such as multiple sclerosis.

    Time frame: Months 0-24 (core study) and Months 24-48 (extension study)

  3. Percent Change in Brain Volume From Month 0 to Month 24 (Core Study) and From Month 24 to Month 48 (Extension Study)

    Calculations of brain volume change were performed using the structural image evaluation of normalized atrophy (SIENA), software included in the Functional Magnetic Resonance Imaging of the Brain (FMRIB) software library. SIENA is a fully automated method for estimating temporal brain volume change.

    Time frame: Months 0-24 (core study) and Months 24-48 (extension study)

  4. Percent Change in Brain Volume From Month 0 End of Study (Core and Extension Study)

    Calculations of brain volume change were performed using the structural image evaluation of normalized atrophy (SIENA), software included in the Functional Magnetic Resonance Imaging of the Brain (FMRIB) software library. SIENA is a fully automated method for estimating temporal brain volume change.

    Time frame: Months 0 to end of study (maximum up to 60 months)

  5. Time to First 3-month Confirmed Disability Progression up to End of Study Based on Expanded Disability Status Scale (EDSS): Kaplan-Meier Estimate of Percentage of Patients Free of Disability Progression

    Kurtzke's Expanded Disability Status Scale (EDSS) is a scale for assessing neurologic impairment in multiple sclerosis (MS) includes a series of scores in each of eight functional systems such as Visual, Brain Stem, Pyramidal, Cerebellar, Sensory, Bowel \& Bladder, Cerebral, and Other. The EDSS steps range from 0 (normal) to 10 (death due to MS). The Kaplan-Meier estimates of the percentage of participants free of disability progression at end of study and their 95% CIs were provided for each treatment group.

    Time frame: Core baseline to end of study (maximum up to 60 months)

07

Results

Posted Jul 12, 2012

Participant flow

Of the 1272 patients randomly assigned to treatment in the Core study (ClinicalTrials.gov ID NCT00289978), 1033 completed the 24-month double-blind treatment phase and were eligible to enter the Extension study. A total of 920 of the 1033 patients entered the Extension study and received treatment.

Core Study (24 Months)
Participant flow — Core Study (24 Months)
MilestoneFingolimod 1.25 mgFingolimod 0.5 mgPlaceboPlacebo-fingolimod 1.25 mgPlacebo-fingolimod 0.5
Started42942541800
Intent to treat (itt)42942541800
Completed33236933200
Not completed97568600
Withdrew: Withdrawal by subject31172800
Withdrew: Adverse event22131800
Withdrew: Unsatisfactory therapeutic effect1362500
Withdrew: Abnormal laboratory value(s)209100
Withdrew: Lost to follow-up35700
Withdrew: Protocol violation55400
Withdrew: Abnormal test procedure result(s)21100
Withdrew: Death10200
Extension Study (Month 24 to 60)
Participant flow — Extension Study (Month 24 to 60)
MilestoneFingolimod 1.25 mgFingolimod 0.5 mgPlaceboPlacebo-fingolimod 1.25 mgPlacebo-fingolimod 0.5
Started2893310145155
Extension intent to treat population2873300145154
From beginning of core at month 242893310145155
From beginning of core at month 302763240136152
From beginning of core at month 362703110130145
From beginning of core at month 422543010120136
From beginning of core at month 4812515205867
From beginning of core at month 54313201113
Completed2452900112126
Not completed444103329
Withdrew: Abnormal laboratory value(s)105083
Withdrew: Abnormal test procedure result(s)31013
Withdrew: Administrative problems00010
Withdrew: Adverse event690610
Withdrew: Lost to follow-up20011
Withdrew: Protocol violation11000
Withdrew: Subject withdrew consent19230159
Withdrew: Subject no longer requires study drug01000
Withdrew: Unsatisfactory therapeutic effect31013

Outcome measures

PrimaryAnnualized Aggregate Relapse Rate (ARR) During Months 0 to End of Study(Core [CFTY720D2301/NCT00289978] and Extension Study)

ARR is defined as the number of confirmed relapses in a year. A relapse is defined as the appearance of a new or worsening of a previously stable or improving pre-existing neurological abnormality, separated by at least 30 days from onset of a preceding relapse. The abnormality must be present for at least 24 hours and occur in the absence of fever or infection. The annualized ARR for each treatment group was the mean of the annualized ARRs for all patients in the group, calculated as the total number of confirmed relapses divided by the total number of days on study multiplied by 365.25.

Time frame:
Months 0 to end of study (maximum up to 60 months)
Reported as:
Number · Relapses per year
Annualized Aggregate Relapse Rate (ARR) During Months 0 to End of Study(Core [CFTY720D2301/NCT00289978] and Extension Study)
Relapses per yearFingolimod 1.25 mgFingolimod 0.5 mgPlacebo-fingolimod
Annualized Aggregate Relapse Rate (ARR) During Months 0 to End of Study(Core [CFTY720D2301/NCT00289978] and Extension Study)0.164 (0.138 to 0.195)0.185 (0.158 to 0.217)0.357 (0.310 to 0.411)
SecondaryChange in Mean Number of New or Newly Enlarged T2 Magnetic Resonance Imaging (MRI) Lesions During Months 0-24 (Core Study) and Months 24-48 (Extension Study)

The number of new or newly enlarged T2 lesions was assessed with T2-weighted MRI scans. A T2-weighted MRI scan utilizes particular values of the echo time (TE) and the repetition time (TR) parameters of image acquisition. Inflammation and tissue damage are seen as bright areas in T2 images and are often referred to as T2 lesions. T2 weighted MRI scans are a sensitive way to evaluate the brain for demyelinating diseases, such as multiple sclerosis.

Time frame:
Months 0-24 (core study) and Months 24-48 (extension study)
Reported as:
Mean · Lesions
Change in Mean Number of New or Newly Enlarged T2 Magnetic Resonance Imaging (MRI) Lesions During Months 0-24 (Core Study) and Months 24-48 (Extension Study)
LesionsFingolimod 1.25 mgFingolimod 0.5 mgPlacebo-fingolimod 1.25 mgPlacebo-fingolimod 0.5 mg
Months 0-242.14 ± 5.2342.66 ± 9.39512.83 ± 17.5738.12 ± 11.083
Months 24-481.71 ± 4.9022.58 ± 9.2562.34 ± 4.7451.43 ± 2.446
Change from Months 0-24 to Months 24-48-0.43 ± 4.393-0.09 ± 7.423-10.48 ± 15.980-6.68 ± 9.876
PrimaryTime to First Confirmed Relapse up to End of Study: Kaplan-Meier Estimate of Percentage of Patients Relapse-free

A relapse was confirmed when it was accompanied by an increase of at least half a step (0.5) on the Expanded Disability Status Scale (EDSS) or an increase of 1 point on two different Functional Systems (FS) of the EDSS or 2 points on one of the FS (excluding Bowel/Bladder or Cerebral FS). Kaplan-Meier estimates of the percentage of relapse-free patients at end of study and and 95% confidence intervals (CIs) were presented for the treatment groups.

Time frame:
Core baseline to end of study (maximum up to 60 months)
Reported as:
Number · Percentage of patients
Time to First Confirmed Relapse up to End of Study: Kaplan-Meier Estimate of Percentage of Patients Relapse-free
Percentage of patientsFingolimod 1.25 mgFingolimod 0.5 mgPlacebo-fingolimod
Time to First Confirmed Relapse up to End of Study: Kaplan-Meier Estimate of Percentage of Patients Relapse-free59.85 (53.90 to 65.80)59.29 (54.17 to 64.41)37.18 (32.15 to 42.22)
SecondaryPercentage of Patients Free of New or Newly Enlarged T2 Magnetic Resonance Imaging (MRI) Lesions During Months 0-24 (Core Study) and Months 24-48 (Extension Study)

The number of new or newly enlarged T2 lesions was assessed with T2-weighted MRI scans. A T2-weighted MRI scan utilizes particular values of the echo time (TE) and the repetition time (TR) parameters of image acquisition. Inflammation and tissue damage are seen as bright areas in T2 images and are often referred to as T2 lesions. T2 weighted MRI scans are a sensitive way to evaluate the brain for demyelinating diseases, such as multiple sclerosis.

Time frame:
Months 0-24 (core study) and Months 24-48 (extension study)
Reported as:
Number · Percentage of patients
Percentage of Patients Free of New or Newly Enlarged T2 Magnetic Resonance Imaging (MRI) Lesions During Months 0-24 (Core Study) and Months 24-48 (Extension Study)
Percentage of patientsFingolimod 1.25 mgFingolimod 0.5 mgPlacebo-fingolimod 1.25 mgPlacebo-fingolimod 0.5 mg
Months 0-2453.250.318.523.2
Months 24-4857.169.352.355.1
SecondaryPercent Change in Brain Volume From Month 0 to Month 24 (Core Study) and From Month 24 to Month 48 (Extension Study)

Calculations of brain volume change were performed using the structural image evaluation of normalized atrophy (SIENA), software included in the Functional Magnetic Resonance Imaging of the Brain (FMRIB) software library. SIENA is a fully automated method for estimating temporal brain volume change.

Time frame:
Months 0-24 (core study) and Months 24-48 (extension study)
Reported as:
Mean · Percent change
Percent Change in Brain Volume From Month 0 to Month 24 (Core Study) and From Month 24 to Month 48 (Extension Study)
Percent changeFingolimod 1.25 mgFingolimod 0.5 mgPlacebo-fingolimod 1.25 mgPlacebo-fingolimod 0.5 mg
Month 0 to Month 24, n=75, 109, 41, 49-1.011 ± 1.3477-0.983 ± 1.6291-1.511 ± 1.6401-1.419 ± 1.3923
Month 24 to Month 48, n=75, 109, 41, 49-0.871 ± 1.4164-0.780 ± 1.9266-1.103 ± 1.4073-0.903 ± 1.1406
PrimaryAnnualized Aggregate Relapse Rate (ARR) During Months 0-24 (Core Study) and Months 24-48 (Extension Study)

ARR is defined as the number of confirmed relapses in a year. A relapse is defined as the appearance of a new or worsening of a previously stable or improving pre-existing neurological abnormality, separated by at least 30 days from onset of a preceding relapse. The abnormality must be present for at least 24 hours and occur in the absence of fever or infection. The annualized ARR for each treatment group was the mean of the annualized ARRs for all patients in the group, calculated as the total number of confirmed relapses divided by the total number of days on study multiplied by 365.25.

Time frame:
Months 0-24 (core study) and Months 24-48 (extension study)
Reported as:
Number · Relapses per year
Annualized Aggregate Relapse Rate (ARR) During Months 0-24 (Core Study) and Months 24-48 (Extension Study)
Relapses per yearFingolimod 1.25 mgFingolimod 0.5 mgPlacebo-fingolimod 1.25 mgPlacebo-fingolimod 0.5 mg
Months 0-240.064 (0.043 to 0.094)0.111 (0.084 to 0.148)0.301 (0.230 to 0.393)0.292 (0.222 to 0.383)
Months 24-480.074 (0.051 to 0.108)0.095 (0.070 to 0.128)0.164 (0.117 to 0.231)0.130 (0.092 to 0.184)
PrimaryChange (Expressed as Ratio) in the Annualized Aggregate Relapse Rate (ARR) From Months 0-24 (Core Study) to Months 24-48 (Extension Study)

ARR is defined as the number of confirmed relapses in a year. A relapse is defined as the appearance of a new or worsening of a previously stable or improving pre-existing neurological abnormality, separated by at least 30 days from onset of a preceding relapse. The abnormality must be present for at least 24 hours and occur in the absence of fever or infection. The annualized ARR for each treatment group was the mean of the annualized ARRs for all patients in the group, calculated as the total number of confirmed relapses divided by the total number of days on study multiplied by 365.25.

Time frame:
Months 0-24 (core study) and Months 24-48 (extension study)
Reported as:
Number · Ratio of relapses per year
Change (Expressed as Ratio) in the Annualized Aggregate Relapse Rate (ARR) From Months 0-24 (Core Study) to Months 24-48 (Extension Study)
Ratio of relapses per yearFingolimod 1.25 mgFingolimod 0.5 mgPlacebo-fingolimod 1.25 mgPlacebo-fingolimod 0.5 mg
Change (Expressed as Ratio) in the Annualized Aggregate Relapse Rate (ARR) From Months 0-24 (Core Study) to Months 24-48 (Extension Study)1.164 (0.830 to 1.633)0.850 (0.658 to 1.099)0.547 (0.390 to 0.767)0.446 (0.320 to 0.620)
SecondaryPercent Change in Brain Volume From Month 0 End of Study (Core and Extension Study)

Calculations of brain volume change were performed using the structural image evaluation of normalized atrophy (SIENA), software included in the Functional Magnetic Resonance Imaging of the Brain (FMRIB) software library. SIENA is a fully automated method for estimating temporal brain volume change.

Time frame:
Months 0 to end of study (maximum up to 60 months)
Reported as:
Mean · Percent change
Percent Change in Brain Volume From Month 0 End of Study (Core and Extension Study)
Percent changeFingolimod 1.25 mgFingolimod 0.5 mgPlacebo-fingolimod
Percent Change in Brain Volume From Month 0 End of Study (Core and Extension Study)-1.639 ± 1.9265-1.674 ± 2.1182-2.241 ± 2.1873
SecondaryTime to First 3-month Confirmed Disability Progression up to End of Study Based on Expanded Disability Status Scale (EDSS): Kaplan-Meier Estimate of Percentage of Patients Free of Disability Progression

Kurtzke's Expanded Disability Status Scale (EDSS) is a scale for assessing neurologic impairment in multiple sclerosis (MS) includes a series of scores in each of eight functional systems such as Visual, Brain Stem, Pyramidal, Cerebellar, Sensory, Bowel \& Bladder, Cerebral, and Other. The EDSS steps range from 0 (normal) to 10 (death due to MS). The Kaplan-Meier estimates of the percentage of participants free of disability progression at end of study and their 95% CIs were provided for each treatment group.

Time frame:
Core baseline to end of study (maximum up to 60 months)
Reported as:
Number · Percentage of patients
Time to First 3-month Confirmed Disability Progression up to End of Study Based on Expanded Disability Status Scale (EDSS): Kaplan-Meier Estimate of Percentage of Patients Free of Disability Progression
Percentage of patientsFingolimod 1.25 mgFingolimod 0.5 mgPlacebo-fingolimod
Time to First 3-month Confirmed Disability Progression up to End of Study Based on Expanded Disability Status Scale (EDSS): Kaplan-Meier Estimate of Percentage of Patients Free of Disability Progression74.15 (69.54 to 78.75)73.90 (69.44 to 78.37)66.28 (61.28 to 71.28)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Fingolimod 1.25mg—31/289 (10.7%)236/289 (81.7%)
Fingolimod 0.5mg—31/331 (9.4%)273/331 (82.5%)
Placebo-Fingolimod 1.25mg—17/145 (11.7%)107/145 (73.8%)
Placebo-Fingolimod 0.5mg—11/155 (7.1%)130/155 (83.9%)
Most frequent serious events
Showing 10 of 92
Most frequent serious events
EventFingolimod 1.25mgFingolimod 0.5mgPlacebo-Fingolimod 1.25mgPlacebo-Fingolimod 0.5mg
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/2893/3312/1450/155
DepressionPsychiatric disorders0/2890/3312/1450/155
Multiple sclerosis relapseNervous system disorders3/2890/3310/1450/155
CholelithiasisHepatobiliary disorders2/2890/3310/1450/155
LymphopeniaBlood and lymphatic system disorders0/2890/3311/1450/155
ThrombocytopeniaBlood and lymphatic system disorders0/2890/3311/1450/155
Atrioventricular block second degreeCardiac disorders0/2890/3311/1450/155
Atrioventricular extrasystolesCardiac disorders0/2890/3311/1450/155
BradycardiaCardiac disorders0/2890/3311/1450/155
Irritable bowel syndromeGastrointestinal disorders0/2890/3311/1450/155
Most frequent other events
Showing 10 of 28
Most frequent other events
EventFingolimod 1.25mgFingolimod 0.5mgPlacebo-Fingolimod 1.25mgPlacebo-Fingolimod 0.5mg
NasopharyngitisInfections and infestations82/28984/33139/14544/155
LymphopeniaBlood and lymphatic system disorders52/28952/33118/14517/155
Upper respiratory tract infectionInfections and infestations39/28958/33123/14524/155
HeadacheNervous system disorders27/28941/33118/14526/155
Alanine aminotransferase increasedInvestigations10/28911/33116/1459/155
InfluenzaInfections and infestations30/28933/3319/14512/155
Lymphocyte count decreasedInvestigations29/28916/33112/14514/155
HypertensionVascular disorders24/28918/33113/14515/155
Back painMusculoskeletal and connective tissue disorders20/28921/33112/14514/155
CoughRespiratory, thoracic and mediastinal disorders19/28927/33113/14511/155

Baseline characteristics

Age Continuous
Age Continuous(years)Fingolimod 1.25 mgFingolimod 0.5 mgPlacebo-fingolimod 1.25 mgPlacebo-fingolimod 0.5 mgTotal
Mean37.2 ± 8.8736.5 ± 8.6036.6 ± 9.2138.1 ± 8.2637.0 ± 8.73
Sex: Female, Male
Sex: Female, Male(Participants)Fingolimod 1.25 mgFingolimod 0.5 mgPlacebo-fingolimod 1.25 mgPlacebo-fingolimod 0.5 mgTotal
Female204234107106651
Male85973849269
08

Study locations

105 sites
  • Novartis Investigative Site
    Chatswood, Australia
  • Novartis Investigative Site
    Fitzroy, 3065, Australia
  • Austin Health, Department of Neurology
    Heidelberg, Australia
  • Novartis Investigative Site
    North Gosford, Australia
  • Novartis Investigative Site
    Woodville, Australia
  • Novartis Investigative Site
    Brugge, Belgium
  • Novartis Investigative Site
    Bruxelles, Belgium
  • Novartis Investigative Site
    Charleroi, Belgium
  • Novartis Investigative Site
    Leuven, Belgium
  • Novartis Investigative Site
    Overpelt, Belgium
  • Novartis Investigative Site
    Sijsele - Damme, Belgium
  • Novartis Investigative Site
    Sint-Truiden, Belgium
  • Novartis Investigative Site
    Halifax, Canada
  • Novartis Investigative Site
    Kingston, Canada
  • Novartis Investigative Site
    London, Canada
  • Novartis Investigative Site
    Montreal, Canada
  • Novartis Investigative Site
    Nepean, Canada
  • Novartis Investigative Site
    Regina, Canada
  • Novartis Investigative Site
    Toronto, Canada
  • Novartis Investigative Site
    Vancouver, Canada
  • Novartis Investigative Site
    Brno, Czech Republic
  • Novartis Investigative Site
    Olomouc, Czech Republic
  • Novartis Investigative Site
    Ostrava-Poruba, Czech Republic
  • Novartis Investigative Site
    Pardubice, Czech Republic
  • Novartis Investigative Site
    Plzen - Lochotin, Czech Republic
  • Novartis Investigative Site
    Prague 5, Czech Republic
  • Novartis Investigative Site
    Praha 2, Czech Republic
  • Novartis Investigative Site
    Rychnov nad Kneznou, Czech Republic
  • Novartis Investigative Site
    Teplice, Czech Republic
  • Novartis Investigative Site
    Talinn, Estonia
  • Novartis Investigative Site
    Helsinki, Finland
  • Novartis Investigative Site
    Tampere, Finland
  • Novartis Investigative Site
    Turku, Finland
  • Novartis Investigative Site
    Clermont Ferrand Cedex, France
  • Novartis Investigative Site
    Dijon, France
  • Novartis Investigative Site
    Lille Cedex, France
  • Novartis Investigative Site
    Marseille cedex 05, France
  • Novartis Investigative Site
    Montpellier cedex 5, France
  • Novartis Investigative Site
    Nantes, France
  • Novartis Investigative Site
    Paris Cedex 13, France
  • Novartis Investigative Site
    Rennes, France
  • Novartis Investigative Site
    Strasbourg, France
  • Novartis Investigative Site
    Berlin, Germany
  • Novartis Investigative Site
    Duesseldorf, Germany
  • Novartis Investigative Site
    Gießen, Germany
  • Novartis Investigative Site
    Hamburg, Germany
  • Novartis Investigative Site
    Leipzig, Germany
  • Novartis Investigative Site
    Magdeburg, Germany
  • Novartis Investigative Site
    Muenchen, Germany
  • Novartis Investigative Site
    Muenster, Germany
  • Novartis Investigative Site
    Regensburg, Germany
  • Novartis Investigative Site
    Stuttgart, Germany
  • Novartis Investigative Site
    Tübingen, Germany
  • Novartis Investigative Site
    Athens, Greece
  • Novartis Investigative Site
    Budapest, Hungary
  • Novartis Investigative Site
    Miskolc, Hungary
  • Novartis Investigative Site
    Szekesfehervar, Hungary
  • Novartis Investigative Site
    Dublin 4, Ireland
  • Novaratis Investigative Site
    Ashkelon, Israel
  • Novartis Investigative Site
    Haifa, Israel
  • Novartis Investigative Site
    Ramat Gan, Israel
  • Novartis Investigative Site
    Safed, Israel
  • Novartis Investigative Site
    Amsterdam, Netherlands
  • Novartis Investigative Site
    Nieuwegein, Netherlands
  • Novartis Investigative Site
    Nijmegen, Netherlands
  • Novartis Investigative Site
    Rotterdam, Netherlands
  • Novartis Investigative Site
    Sittard, Netherlands
  • Novartis Investigative Site
    Tilburg, Netherlands
  • Novartis Investigative Site
    Bialystok, Poland
  • Novartis Investigative Site
    Gdansk, Poland
  • Novartis Investigative Site
    Katowice, Poland
  • Novartis Investigative Site
    Lodz, Poland
  • Novartis Investigative Site
    Poznan, Poland
  • Novartis Investigative Site
    Warsaw, Poland
  • Novartis Investigative Site
    Warszawa, Poland
  • Novartis Investigative Site
    Bucharest, Romania
  • Novartis Investigative Site
    Craiova, Romania
  • Novartis Investigative Site
    Lasi, Romania
  • Novartis Investigative Site
    Tg. Mures, Romania
  • Novartis Investigative Site
    Kazan, Russian Federation
  • Novartis Investigative Site
    Moscow, Russian Federation
  • Novartis Investigative Site
    St. Petersburg, Russian Federation
  • Novartis Investigational Site
    Bratislava, Slovakia
  • Novartis Investigative Site
    Martin, Slovakia
  • Novartis Investigational Site
    Zilina, Slovakia
  • Novartis Investigational Site
    Cape Town, South Africa
  • Novartis Investigational Site
    Rosebank, South Africa
  • Novartis Investigational Site
    Umhlanga, South Africa
  • Novartis Investigational Site
    Göteborg, Sweden
  • Novartis Investigational Site
    Stockholm, Sweden
  • Novartis Investigative Site
    Lausanne, Switzerland
  • Novartis Investigative Site
    Zuerich, Switzerland
  • Novartis Investigational Site
    Ankara, Turkey
  • Novartis Investigational Site
    Bursa, Turkey
  • Novartis Investigational Site
    Cerrahpasa/Istanbul, Turkey
  • Novartis Investigational Site
    Gaziantep, Turkey
  • Novartis Investigational Site
    Istanbul, Turkey
  • Novartis Investigational Site
    Izmir, Turkey
  • Novartis Investigational Site
    Mersin, Turkey
  • Novartis Investigational Site
    Yenisehir/Izmir, Turkey

Showing the first 100 of 105 sites across 22 countries. Choose a country and city above to see the rest.

09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2008, a primary completion of Jun 2011 and a completion of Jun 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2012, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2008
First posted
Apr 21, 2008
Start
Feb 2008
Primary completionActual
Jun 2011
CompletionActual
Jun 2011
Results first posted
Jul 12, 2012
Last update
Jul 12, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 12, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00662649
Lead sponsor
Novartis
Responsible party
Sponsor
First posted
Apr 21, 2008
Start date
Feb 2008
Primary completion
Jun 2011
Completion
Jun 2011
Results posted
Jul 12, 2012
Last update
Jul 12, 2012

Study contacts

Novartis Pharmaceuticals
study chair · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fingolimod

Start the discussion